BridgeBio Oncology Therapeutics (BBOT) AI Stock Analysis

• Market Cap: $833.94M
• Dividend Yield: N/A
• Average Volume (3M): 344.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.07
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 62
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 80,032,820
• 10 Day Avg. Volume: 232,276
• 30 Day Avg. Volume: 344,973
• PEG Ratio: <0.01
• Price to Book (P/B): 0.95
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.41
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.38K
• Enterprise Value/Ebitda: -3.19
• 1Y Price Target: $25.38
• Price Target Upside: 101.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $10.00 ▼(-20.57% Downside)
• Action: N/A Date: 03/06/26
• Date: Action: N/A 03/06/26

BBOT scores mid-range primarily because a strong, low-leverage balance sheet is offset by being pre-revenue with widening losses and heavy cash burn. Technical indicators add pressure given a below-moving-average, negative-MACD setup, while recent positive clinical updates provide a meaningful but not fully offsetting catalyst. Valuation is constrained by negative earnings and no dividend.

Positive Factors

Low financial leverage

Very low debt relative to a sizable equity base materially reduces refinancing and solvency risk for a pre-revenue biotech. This balance-sheet strength gives management flexibility to fund clinical programs, pursue partnerships, and time external raises more strategically, supporting multi‑quarter operational continuity.

Promising clinical efficacy and safety

Robust efficacy signals and a differentiated safety profile in lead programs materially de‑risk development pathways. Durable responses, favorable liver safety and combination activity with pembrolizumab position assets for front‑line use or partnerships, strengthening long‑term commercial prospects in targeted oncology.

Improved capitalization

A meaningful increase in equity improves the funding runway and reduces immediate liquidity stress. Stronger capitalization supports continued R&D investment and staged development of multiple programs, enabling the company to advance trials without immediate dilutive financing and pursue strategic collaborations.

Negative Factors

Pre-revenue with widening losses

The company remains pre‑revenue while operating and net losses have widened substantially, indicating rising development costs without offsetting commercial cash inflows. This structural gap means long‑term viability depends on successful trials or continued external funding rather than internal cash generation.

High and persistent cash burn

Large negative operating and free cash flow reflects sustained burn to progress multiple clinical programs. Continued negative cash generation increases dependency on capital markets or partnerships, heightens dilution risk for shareholders, and constrains ability to scale development or commercialization without external support.

Negative return on equity / capital efficiency

Despite a larger equity base, returns remain negative, indicating poor capital efficiency: invested capital funds R&D losses rather than generating returns. Over time this undermines investor value unless clinical successes translate into revenue, increasing pressure for future financings or strategic restructurings.

BridgeBio Oncology Therapeutics Business Overview & Revenue Model

Company Description

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

How the Company Makes Money

BridgeBio Oncology Therapeutics Financial Statement Overview

Summary

Overall financials are mixed: a strong, low-debt balance sheet (debt about $2.8M vs. equity about $411.1M) and improved capitalization are positives, but the company remains pre-revenue with materially widening losses (net loss about $74.3M to about $134.0M) and significant ongoing cash burn (operating cash flow about -$113.9M; free cash flow about -$114.5M).

Income Statement

BBOT is still pre-revenue (no revenue reported across the provided annual periods), and losses have widened materially, with net loss increasing from about $74.3M (2024) to about $134.0M (2025). Operating losses also expanded sharply (EBIT roughly -$80.9M to -$145.8M), indicating a higher cost base and limited near-term operating leverage. Strength: the company appears to be scaling R&D/investment activity (typical for biotech), but the lack of revenue and accelerating losses are clear pressure points.

Balance Sheet

The balance sheet looks relatively strong on leverage: debt is minimal in 2025 (about $2.8M) versus equity of about $411.1M, implying very low financial leverage. Total assets are sizable (about $448.4M) and equity increased significantly versus 2024 (about $188.7M), suggesting improved capitalization. Key weakness: profitability remains deeply negative (negative return on equity in 2024–2025), meaning the equity base is being used to fund ongoing losses rather than generating returns.

Cash Flow

Cash generation remains a major weakness: operating cash flow and free cash flow are both negative in 2025 (about -$113.9M and -$114.5M), reflecting continued cash burn to fund operations. A positive signal is that free cash flow tracked net loss closely in 2025 (roughly in line with net income loss), suggesting limited additional cash leakage beyond accounting losses. However, the magnitude of annual burn is high and ongoing, and cash flow coverage metrics are negative, underscoring reliance on external funding until revenue materializes.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-610.00K	0.00	0.00	0.00	0.00
EBITDA	-145.82M	-80.66M	-64.68M	-3.52K	-43.36K
Net Income	-134.04M	-74.28M	-64.70M	-3.52K	-43.36K
Balance Sheet
Total Assets	448.38M	194.42M	332.89K	144.58K	144.28K
Cash, Cash Equivalents and Short-Term Investments	425.46M	1.70M	0.00	0.00	0.00
Total Debt	2.77M	0.00	70.09K	43.11K	36.96K
Total Liabilities	37.28M	5.71M	396.46K	166.46K	162.64K
Stockholders Equity	411.10M	188.72M	-63.57K	-21.88K	-18.36K
Cash Flow
Free Cash Flow	-114.50M	-763.82K	0.00	0.00	0.00
Operating Cash Flow	-113.89M	-763.82K	0.00	0.00	0.00
Investing Cash Flow	73.33M	-184.00M	0.00	0.00	0.00
Financing Cash Flow	383.40M	186.46M	0.00	0.00	0.00

BridgeBio Oncology Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BBOT	50 Neutral	$833.94M	-2.91	2.53%	―	―	―

BridgeBio Oncology Therapeutics Corporate Events

BridgeBio Oncology reports promising RAS and PI3Kα data

On January 7, 2026, BridgeBio Oncology Therapeutics reported positive preliminary clinical data across all three of its RAS and PI3Kα pipeline programs, highlighting both efficacy signals and differentiated safety profiles that could strengthen its competitive positioning in targeted oncology. Lead asset BBO‑8520 showed a 65% objective response rate and 66% six‑month progression‑free survival as monotherapy in KRAS G12C non‑small cell lung cancer as of November 15, 2025, with durable responses and a generally well‑tolerated safety profile, while combination therapy with pembrolizumab produced tumor reductions in all evaluable patients, partial responses in frontline and previously KRAS G12C‑treated patients, and a favorable liver safety profile, suggesting potential as a front‑line immunotherapy partner. BBO‑11818, in the KONQUER‑101 Phase 1 trial, demonstrated encouraging anti‑tumor activity as of December 10, 2025, including a partial response with 44% tumor reduction in pretreated pancreatic ductal adenocarcinoma and generally tolerable safety at escalating doses that cover key KRAS mutant alleles, underscoring the promise of a panKRAS approach. BBO‑10203 showed a differentiated safety profile with no hyperglycemia events and no baseline glucose or HbA1c restrictions, and BBOT has already initiated combination studies with standard‑of‑care regimens in colorectal and breast cancer, with internal combinations with BBO‑8520 and BBO‑11818 expected to follow, indicating a strategic push toward multi‑agent regimens that may enhance treatment options for aggressive, RAS‑driven cancers and support the company’s longer‑term growth trajectory in precision oncology.

The most recent analyst rating on (BBOT) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BridgeBio Oncology Therapeutics stock, see the BBOT Stock Forecast page.